Health Condition 1: null- Patients who had arterial or venous stroke
Conditions
Interventions
Intervention1: Levetiracetam 250 mg- oral tablet: If the weight of the patient is less than 75 kg, he/she will receive one tablet twice a day for 1 week followed by 2 tablets twice a day for 3 months
Sponsors
Department of Science and Technology
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with either ischemic stroke (arterial or venous occlusion) or parenchymal intracerebral haemorrhage (spontaneous non-aneurysmal, non-traumatic intracerebral haemorrhage) with a cortical syndrome (either parenchymal involvement documented by imaging (CT/MRI) or presence of seizures, aphasia, apraxia or agnosia) 2. Presenting within 1 week of onset in arterial stroke and within 2 weeks of confirmation of ICVT.
Exclusion criteria
Exclusion criteria: 1. Previous history of epilepsy or treatment with an AED 2. Life expectation less than 1 month due to stroke or other life-threatening comorbidity 3. Subarachnoid or intraventricular hemorrhage 4. Isolated posterior circulation stroke involving brainstem or cerebellum 5. ICVT without cortical syndrome (clinical or radiological) 6. ICH due to brain tumor, trauma, vascular malformation, brain surgery or infection 7. Pre-existing dementia 8. Known allergy to Levieracetam
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence of a seizure.Timepoint: one year | — |
Secondary
| Measure | Time frame |
|---|---|
| time from stroke to occurrence of a seizure, occurrence of early epileptic seizures after stroke, seizure severity, neurological function, midline shift, enlargement of hematoma, death (all cause), functional outcome assessed by Glasgow Outcome Scale and modified Rankin Scale and the occurrence of side effects of the trial medicationTimepoint: one year | — |
Countries
India
Contacts
Public ContactVishnu VY
AIIMS, NewDelhi
Outcome results
None listed